Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1817080 dose-finding in refractory and/or unexplained chronic cough
2019-004169-42Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eliapixant in refractory chronic cough (RCC) and chronic cough (3 arms), sponsored by Bayer. Primary endpoint: Change from baseline in 24-hour cough count. Started Feb 2020; status: completed.
02
Drugs
eliapixant
03
Conditions
refractory chronic cough (RCC)chronic cough
Beyond the preview
Go deeper on 2019-004169-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004169-42.